Decrease in APP and CP mRNA expression supports impairment of iron export in Alzheimer's disease patients

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1852, Issue 10, 2015, Pages 2116-2122

  Guerreiro, Cláudia ^a   Silva, Bruno ^a   Crespo, Ângela C ^a,b   Marques, Liliana ^a,c   Costa, Sónia ^d   Timóteo, Ângela ^d   Marcelino, Erica ^e   Maruta, Carolina ^e   Vilares, Arminda ^a   Matos, Mafalda ^e   Couto, Frederico Simões ^e   Faustino, Paula ^a   Verdelho, Ana ^e   Guerreiro, Manuela ^e   Herrero, Ana ^d   Costa, Cristina ^d   de Mendonça, Alexandre ^e   Martins, Madalena ^b,e   Costa, Luciana ^a,c  

^a NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

^b INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

^c UNIVERSITY OF LISBON   (Portugal)

^d B Surgery Department   (Portugal)

^e INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Alzheimer's disease; Cellular iron export; Gene expression; Iron homeostasis

Indexed keywords

ACONITATE HYDRATASE; AMYLOID PRECURSOR PROTEIN; CERULOPLASMIN; FERROPORTIN; MESSENGER RNA;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; HOMEOSTASIS; HUMAN; IRON TRANSPORT; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84938261417     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2015.07.017     Document Type: Article

References (64)

1. Wortmann M. Dementia: a global health priority - highlights from an ADI and World Health Organization report. Alzheimers Res. Ther. 2012, 4:40.
2. Armstrong R.A. The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer's disease. Folia Neuropathol. 2009, 47:289-299.
3. Walsh D.M., Selkoe D.J. A beta oligomers - a decade of discovery. J. Neurochem. 2007, 101:1172-1184.
4. Duce J.A., Bush A.I. Biological metals and Alzheimer's disease: implications for therapeutics and diagnostics. Prog. Neurobiol. 2010, 92:1-18.
5. Leskovjan A.C., Kretlow A., Lanzirotti A., Barrea R., Vogt S., Miller L.M. Increased brain iron coincides with early plaque formation in a mouse model of Alzheimer's disease. NeuroImage 2011, 55:32-38.
6. Liu B., Moloney A., Meehan S., Morris K., Thomas S.E., Serpell L.C., Hider R., Marciniak S.J., Lomas D.A., Crowther D.C. Iron promotes the toxicity of amyloid beta peptide by impeding its ordered aggregation. J. Biol. Chem. 2011, 286:4248-4256.
7. Smith M.A., Harris P.L., Sayre L.M., Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:9866-9868.
8. Schubert D., Chevion M. The role of iron in beta amyloid toxicity. Biochem. Biophys. Res. Commun. 1995, 216:702-707.
9. Roberts B.R., Ryan T.M., Bush A.I., Masters C.L., Duce J.A. The role of metallobiology and amyloid-beta peptides in Alzheimer's disease. J. Neurochem. 2012, 120(Suppl. 1):149-166.
10. Rottkamp C.A., Raina A.K., Zhu X., Gaier E., Bush A.I., Atwood C.S., Chevion M., Perry G., Smith M.A. Redox-active iron mediates amyloid-beta toxicity. Free Radic. Biol. Med. 2001, 30:447-450.
11. Rival T., Page R.M., Chandraratna D.S., Sendall T.J., Ryder E., Liu B., Lewis H., Rosahl T., Hider R., Camargo L.M., Shearman M.S., Crowther D.C., Lomas D.A. Fenton chemistry and oxidative stress mediate the toxicity of the beta-amyloid peptide in a Drosophila model of Alzheimer's disease. Eur. J. Neurosci. 2009, 29:1335-1347.
12. Bush A.I. The metal theory of Alzheimer's disease. J. Alzheimers Dis. 2013, 33(Suppl. 1):S277-S281.
13. Zecca L., Youdim M.B., Riederer P., Connor J.R., Crichton R.R. Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 2004, 5:863-873.
14. Crichton R.R., Dexter D.T., Ward R.J. Brain iron metabolism and its perturbation in neurological diseases. J. Neural Transm. 2011, 118:301-314.
15. Ward R.J., Zucca F.A., Duyn J.H., Crichton R.R., Zecca L. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 2014, 13:1045-1060.
16. Barnham K.J., Bush A.I. Biological metals and metal-targeting compounds in major neurodegenerative diseases. Chem. Soc. Rev. 2014, 43:6727-6749.
17. Rogers J.T., Randall J.D., Cahill C.M., Eder P.S., Huang X., Gunshin H., Leiter L., McPhee J., Sarang S.S., Utsuki T., Greig N.H., Lahiri D.K., Tanzi R.E., Bush A.I., Giordano T., Gullans S.R. An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J. Biol. Chem. 2002, 277:45518-45528.
18. McKie A.T., Marciani P., Rolfs A., Brennan K., Wehr K., Barrow D., Miret S., Bomford A., Peters T.J., Farzaneh F., Hediger M.A., Hentze M.W., Simpson R.J. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol. Cell 2000, 5:299-309.
19. Donovan A., Brownlie A., Zhou Y., Shepard J., Pratt S.J., Moynihan J., Paw B.H., Drejer A., Barut B., Zapata A., Law T.C., Brugnara C., Lux S.E., Pinkus G.S., Pinkus J.L., Kingsley P.D., Palis J., Fleming M.D., Andrews N.C., Zon L.I. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 2000, 403:776-781.
20. Duce J.A., Tsatsanis A., Cater M.A., James S.A., Robb E., Wikhe K., Leong S.L., Perez K., Johanssen T., Greenough M.A., Cho H.H., Galatis D., Moir R.D., Masters C.L., McLean C., Tanzi R.E., Cappai R., Barnham K.J., Ciccotosto G.D., Rogers J.T., Bush A.I. Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell 2010, 142:857-867.
21. Ebrahimi K.H., Hagedoorn P.L., Hagen W.R. A synthetic peptide with the putative iron binding motif of amyloid precursor protein (APP) does not catalytically oxidize iron. PLoS One 2012, 7:e40287.
22. Honarmand Ebrahimi K., Dienemann C., Hoefgen S., Than M.E., Hagedoorn P.L., Hagen W.R. The amyloid precursor protein (APP) does not have a ferroxidase site in its E2 domain. PLoS One 2013, 8:e72177.
23. Wong B.X., Tsatsanis A., Lim L.Q., Adlard P.A., Bush A.I., Duce J.A. beta-Amyloid precursor protein does not possess ferroxidase activity but does stabilize the cell surface ferrous iron exporter ferroportin. PLoS One 2014, 9:e114174.
24. McCarthy R.C., Park Y.H., Kosman D.J. sAPP modulates iron efflux from brain microvascular endothelial cells by stabilizing the ferrous iron exporter ferroportin. EMBO Rep. 2014, 15:809-815.
25. Rogers J.T., Leiter L.M., McPhee J., Cahill C.M., Zhan S.S., Potter H., Nilsson L.N. Translation of the Alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5'-untranslated region sequences. J. Biol. Chem. 1999, 274:6421-6431.
26. Sampath P., Mazumder B., Seshadri V., Fox P.L. Transcript-selective translational silencing by gamma interferon is directed by a novel structural element in the ceruloplasmin mRNA 3' untranslated region. Mol. Cell. Biol. 2003, 23:1509-1519.
27. Takahashi M., Dore S., Ferris C.D., Tomita T., Sawa A., Wolosker H., Borchelt D.R., Iwatsubo T., Kim S.H., Thinakaran G., Sisodia S.S., Snyder S.H. Amyloid precursor proteins inhibit heme oxygenase activity and augment neurotoxicity in Alzheimer's disease. Neuron 2000, 28:461-473.
28. Altamura S., Muckenthaler M.U. Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. J. Alzheimers Dis. 2009, 16:879-895.
29. Silvestri L., Camaschella C. A potential pathogenetic role of iron in Alzheimer's disease. J. Cell. Mol. Med. 2008, 12:1548-1550.
30. Silvestri L., Pagani A., Camaschella C. Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood 2008, 111:924-931.
31. Babitt J.L., Huang F.W., Wrighting D.M., Xia Y., Sidis Y., Samad T.A., Campagna J.A., Chung R.T., Schneyer A.L., Woolf C.J., Andrews N.C., Lin H.Y. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat. Genet. 2006, 38:531-539.
32. Hussain R.I., Ballard C.G., Edwardson J.A., Morris C.M. Transferrin gene polymorphism in Alzheimer's disease and dementia with Lewy bodies in humans. Neurosci. Lett. 2002, 317:13-16.
33. Lleó A., Blesa R., Angelopoulos C., Pastor-Rubio P., Villa M., Oliva R., Bufill E. Transferrin C2 allele, haemochromatosis gene mutations, and risk for Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2002, 72:820-821.
34. Coon K.D., Siegel A.M., Yee S.J., Dunckley T.L., Mueller C., Nagra R.M., Tourtellotte W.W., Reiman E.M., Papassotiropoulos A., Petersen F.F., Stephan D.A., Kirsch W.M. Preliminary demonstration of an allelic association of the IREB2 gene with Alzheimer's disease. J. Alzheimers Dis. 2006, 9:225-233.
35. Kauwe J.S., Bertelsen S., Mayo K., Cruchaga C., Abraham R., Hollingworth P., Harold D., Owen M.J., Williams J., Lovestone S., Morris J.C., Goate A.M. Suggestive synergy between genetic variants in TF and HFE as risk factors for Alzheimer's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010, 153B:955-959.
36. Lehmann D.J., Schuur M., Warden D.R., Hammond N., Belbin O., Kolsch H., Lehmann M.G., Wilcock G.K., Brown K., Kehoe P.G., Morris C.M., Barker R., Coto E., Alvarez V., Deloukas P., Mateo I., Gwilliam R., Combarros O., Arias-Vasquez A., Aulchenko Y.S., Ikram M.A., Breteler M.M., van Duijn C.M., Oulhaj A., Heun R., Cortina-Borja M., Morgan K., Robson K., Smith A.D. Transferrin and HFE genes interact in Alzheimer's disease risk: the Epistasis Project. Neurobiol. Aging 2012, 33:202. (e201-213).
37. Crespo A.C., Silva B., Marques L., Marcelino E., Maruta C., Costa S., Timoteo A., Vilares A., Couto F.S., Faustino P., Correia A.P., Verdelho A., Porto G., Guerreiro M., Herrero A., Costa C., de Mendonca A., Costa L., Martins M. Genetic and biochemical markers in patients with Alzheimer's disease support a concerted systemic iron homeostasis dysregulation. Neurobiol. Aging 2014, 35:777-785.
38. Huang C.-W., Wang S.-J., Wu S.-J., Yang C.-C., Huang M.-W., Lin C.-H., Cheng I.H. Potential blood biomarker for disease severity in the Taiwanese population with Alzheimer's disease. Am. J. Alzheimers Dis. Other Demen. 2013, 28:75-83.
39. Torsdottir G., Kristinsson J., Snaedal J., Jóhannesson T. Ceruloplasmin and iron proteins in the serum of patients with Alzheimer's disease. Dement. Geriatr. Cogn. Dis. Extra 2011, 1:366-371.
40. Vural H., Demirin H., Kara Y., Eren I., Delibas N. Alterations of plasma magnesium, copper, zinc, iron and selenium concentrations and some related erythrocyte antioxidant enzyme activities in patients with Alzheimer's disease. J. Trace Elem. Med. Biol. 2010, 24:169-173.
41. Bomboi G., Marchione F., Sepe-Monti M., De Carolis A., Bianchi V., Medda E., Pino A., Bocca B., Forte G., D'Ippolito C., Giubilei F. Correlation between metal ions and clinical findings in subjects affected by Alzheimer's disease. Ann. Ist. Super. Sanita 2005, 41:205-212.
42. Tao Y., Wang Y., Rogers J.T., Wang F. Perturbed iron distribution in Alzheimer's disease serum, cerebrospinal fluid, and selected brain regions: a systematic review and meta-analysis. J. Alzheimers Dis. 2014, 42:679-690.
43. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
44. Schosinsky K.H., Lehmann H.P., Beeler M.F. Measurement of ceruloplasmin from its oxidase activity in serum by use of o-dianisidine dihydrochloride. Clin. Chem. 1974, 20:1556-1563.
45. Gonzalez J.R., Armengol L., Sole X., Guino E., Mercader J.M., Estivill X., Moreno V. SNPassoc: an R package to perform whole genome association studies. Bioinformatics 2007, 23:644-645.
46. Harris Z.L., Durley A.P., Man T.K., Gitlin J.D. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:10812-10817.
47. Jeong S.Y., David S. Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J. Biol. Chem. 2003, 278:27144-27148.
48. Marques L., Auriac A., Willemetz A., Banha J., Silva B., Canonne-Hergaux F., Costa L. Immune cells and hepatocytes express glycosylphosphatidylinositol-anchored ceruloplasmin at their cell surface. Blood Cells Mol. Dis. 2012, 48:110-120.
49. Patel B.N., Dunn R.J., David S. Alternative RNA splicing generates a glycosylphosphatidylinositol-anchored form of ceruloplasmin in mammalian brain. J. Biol. Chem. 2000, 275:4305-4310.
50. Hellman N.E., Gitlin J.D. Ceruloplasmin metabolism and function. Annu. Rev. Nutr. 2002, 22:439-458.
51. Patel B.N., Dunn R.J., Jeong S.Y., Zhu Q., Julien J.P., David S. Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury. J. Neurosci. 2002, 22:6578-6586.
52. Nittis T., Gitlin J.D. The copper-iron connection: hereditary aceruloplasminemia. Semin. Hematol. 2002, 39:282-289.
53. Hellman N.E., Kono S., Miyajima H., Gitlin J.D. Biochemical analysis of a missense mutation in aceruloplasminemia. J. Biol. Chem. 2002, 277:1375-1380.
54. Banha J., Marques L., Oliveira R., Martins Mde F., Paixao E., Pereira D., Malho R., Penque D., Costa L. Ceruloplasmin expression by human peripheral blood lymphocytes: a new link between immunity and iron metabolism. Free Radic. Biol. Med. 2008, 44:483-492.
55. Kummer M.P., Heneka M.T. Truncated and modified amyloid-beta species. Alzheimers Res. Ther. 2014, 6:28.
56. Bandyopadhyay S., Cahill C., Balleidier A., Huang C., Lahiri D.K., Huang X., Rogers J.T. Novel 5' untranslated region directed blockers of iron-regulatory protein-1 dependent amyloid precursor protein translation: implications for down syndrome and Alzheimer's disease. PLoS One 2013, 8:e65978.
57. Cho H.H., Cahill C.M., Vanderburg C.R., Scherzer C.R., Wang B., Huang X., Rogers J.T. Selective translational control of the Alzheimer amyloid precursor protein transcript by iron regulatory protein-1. J. Biol. Chem. 2010, 285:31217-31232.
58. Raha A.A., Vaishnav R.A., Friedland R.P., Bomford A., Raha-Chowdhury R. The systemic iron-regulatory proteins hepcidin and ferroportin are reduced in the brain in Alzheimer's disease. Acta Neuropathol. Commun. 2013, 1:55.
59. Rouault T.A. The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat. Chem. Biol. 2006, 2:406-414.
60. Mueller C., Magaki S., Schrag M., Ghosh M.C., Kirsch W.M. Iron regulatory protein 2 is involved in brain copper homeostasis. J. Alzheimers Dis. 2009, 18:201-210.
61. Luo Q.Q., Wang D., Yu M.Y., Zhu L. Effect of hypoxia on the expression of iron regulatory proteins 1 and the mechanisms involved. IUBMB Life 2011, 63:120-128.
62. Daulatzai M.A. Death by a thousand cuts in Alzheimer's disease: hypoxia-the prodrome. Neurotox. Res. 2013, 24:216-243.
63. Harada N., Kanayama M., Maruyama A., Yoshida A., Tazumi K., Hosoya T., Mimura J., Toki T., Maher J.M., Yamamoto M., Itoh K. Nrf2 regulates ferroportin 1-mediated iron efflux and counteracts lipopolysaccharide-induced ferroportin 1 mRNA suppression in macrophages. Arch. Biochem. Biophys. 2011, 508:101-109.
64. Marro S., Chiabrando D., Messana E., Stolte J., Turco E., Tolosano E., Muckenthaler M.U. Heme controls ferroportin1 (FPN1) transcription involving Bach1, Nrf2 and a MARE/ARE sequence motif at position -7007 of the FPN1 promoter. Haematologica 2010, 95:1261-1268.